CAR T-Cell Therapy for ALL
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.
Clinical Pearls
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.
- Adult patients with relapsed ALL have a poor prognosis overall survival is less than 10%.
- This CD-19-targeted CAR modified T-cell therapy elicited an 80% complete remission rate.
- The vast majority of these responses were MRD-negative.
<<<
Recent Videos
Related Content
